Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users

Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clinical validity and utility of pre-emptive pharmacogenomics screening i...

Full description

Saved in:
Bibliographic Details
Published in:Genes 2023-02, Vol.14 (2), p.456
Main Authors: Jansen, Marleen E, Rigter, Tessel, Fleur, Thom M C, Souverein, Patrick C, Verschuren, W M Monique, Vijverberg, Susanne J, Swen, Jesse J, Rodenburg, Wendy, Cornel, Martina C
Format: Article
Language:English
Subjects:
Cholesterol
Clinical medicine
Cohort analysis
Collaboration
Drug dosages
Family physicians
Gene polymorphism
Genotype & phenotype
Musculoskeletal system
Patients
Pharmacogenomics
Pharmacy
Polymorphism
Population
Primary care
Risk factors
Statins
Validity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clinical validity and utility of pre-emptive pharmacogenomics screening in primary care, with c.521T>C as a risk factor for statin-induced adverse drug reactions. The focus was on changes in therapy as a proxy for adverse drug reactions observed in statin-users in a population-based Dutch cohort. In total, 1136 statin users were retrospectively genotyped for the c.521T>C polymorphism (rs4149056) and information on their statin dispensing was evaluated as cross-sectional research. Approximately half of the included participants discontinued or switched their statin treatment within three years. In our analyses, we could not confirm an association between the c.521T>C genotype and any change in statin therapy or arriving at a stable dose sooner in primary care. To be able to evaluate the predictive values of c.521T>C genotype on adverse drug reactions from statins, prospective data collection of actual adverse drug reactions and reasons to change statin treatment should be facilitated.
ISSN:2073-4425
2073-4425
DOI:10.3390/genes14020456